Login to Your Account



Amicus' Six-Month Fabry Data a Near Miss; Shares Nosedive

By Catherine Shaffer
Staff Writer

Friday, December 21, 2012

A Phase III trial by Amicus Therapeutics Inc., of Cranbury, N.J., and GlaxoSmithKline plc, of London, testing a drug candidate for Fabry disease missed its primary and secondary endpoints.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription